Published in Drug Week, April 24th, 2009
"The risk of death at 16 years of follow-up among 3026 patients with coronary heart disease allocated to the original bezafibrate (n=1509) and placebo (n=1517) arms of the Bezafibrate Infarction Prevention (BIP) trial was related to HDL-C response to bezafibrate therapy, categorized as upper-tertile (> 8 mg/dL) or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.